Seniors vs. UnitedHealth: A Post-Chevron Legal Showdown

SAN FRANCISCO, CA – March 31, 2026 – The nation’s healthcare and legal landscapes are bracing for a landmark decision from the Ninth Circuit Court of Appeals in a case that pits vulnerable senior citizens against UnitedHealth Group, America’s largest for-profit Medicare Advantage provider. The ruling in Estate of Bibi Ahmad v. UnitedHealth Group Inc. will determine if the healthcare giant can continue to use a powerful federal preemption defense to shield itself from state-level fraud and elder abuse claims—a legal battleground dramatically reshaped by the U.S. Supreme Court's 2024 decision to overturn the long-standing Chevron doctrine.

The appeal challenges a lower court's dismissal of a national class action lawsuit alleging that UnitedHealth engaged in a decade-long campaign of deceptive marketing to push seniors out of Original Medicare and into its corporate-run Medicare Advantage plans. The outcome could set a monumental precedent, potentially dismantling a legal shield used by insurers for decades and redefining corporate accountability in the trillion-dollar healthcare industry.

The Post-Chevron Legal Battlefield

At the heart of the appeal is a seismic shift in American administrative law. On June 28, 2024, the Supreme Court overturned Chevron v. Natural Resources Defense Council, a 40-year-old precedent that required courts to defer to a federal agency's reasonable interpretation of an ambiguous law. In a 6-3 decision, the Court declared that the judiciary, not federal agencies, has the ultimate authority to “say what the law is.”

This ruling directly impacts the core of UnitedHealth’s defense. For years, large corporations have argued that comprehensive federal regulations, such as those governing Medicare Advantage by the Centers for Medicare & Medicaid Services (CMS), preempt state consumer protection laws. Under Chevron, courts often deferred to an agency's interpretation of its own preemptive power. With Chevron gone, the Ninth Circuit is no longer required to give any special weight to CMS regulations that may override state-level protections.

“With Chevron gone, courts are no longer required to defer to CMS regulations that override consumer protections granted by Congress,” said lead counsel for the plaintiffs, Gloria Juarez. “The Medicare Act has never expressly preempted state law protections. Preemption has become a get-out-of-jail-free card for gorilla-sized healthcare corporations—especially in elder abuse and fraud contexts.”

The plaintiffs argue that the district court's dismissal on preemption grounds was improper in this new legal environment. The Ninth Circuit must now conduct its own independent analysis to decide if Congress ever intended for the Medicare Act to nullify state laws designed to protect consumers from false advertising and unfair business practices.

A Human Toll: Allegations of Deception and Denied Care

While the legal arguments are complex, the allegations at the center of the lawsuit paint a stark and human picture. The complaint, filed under California’s False Advertising Law, Unfair Competition Law, and Consumers Legal Remedies Act, claims UnitedHealth used a sophisticated campaign of emails, direct mail, and television ads to mislead seniors. The suit alleges these materials misrepresented their Medicare Advantage plans as a simple enhancement or extension of Original Medicare, when in reality, enrollment required seniors to completely surrender their traditional Medicare benefits.

The consequences, according to the lawsuit, were devastating for some. One plaintiff, a 96-year-old cancer patient identified as D.D., was allegedly persuaded to switch plans. Subsequently, she was denied access to her long-time cancer specialists, causing critical delays in her treatment. While her health deteriorated, she was sued by providers for unpaid bills that UnitedHealthcare refused to cover. The complaint asserts that all the while, the company was reporting her enrollment to CMS to collect federal bonuses.

In dismissing the case, U.S. District Judge Monica Ramirez Almadani nevertheless noted the gravity of the claims, writing, “This Court does not minimize the seriousness of the allegations in the Complaint or the grave issues in addressing vulnerable populations’ access to healthcare.”

“We are fighting not just for accountability for what happened to Ms. Ahmad, D.D., and G.L., but to protect other families from unknowingly giving up their Medicare benefits through slick sales pitches and corporate greed,” Juarez stated. The lawsuit seeks to certify a class action that could include hundreds of thousands of seniors across the country who were allegedly affected by these practices.

Profits, Patients, and a Scrutinized Industry

The legal battle unfolds against a backdrop of immense profitability for UnitedHealth and growing scrutiny of the entire Medicare Advantage industry. In 2023, UnitedHealth Group reported staggering revenues of $371.6 billion and net earnings of over $22 billion. Plaintiffs argue this financial success was fueled, in part, by practices designed to maximize revenue at the expense of patient care.

Consumer advocacy groups and government watchdogs have long raised alarms about the Medicare Advantage program. Allegations of “risk adjustment fraud,” or “upcoding,” are rampant. This practice involves plans exaggerating patient illnesses to receive higher monthly payments from the government. Reports have indicated that some large insurers assign patients risk scores significantly higher than average, costing taxpayers billions.

Furthermore, the industry is frequently criticized for aggressive prior authorization requirements and high rates of care denial, which obstruct access to necessary medical services. A separate 2025 Ninth Circuit ruling in A.G.G. et al. v. UHC revived a class action against UnitedHealthcare for its alleged “wrongful and systematic denial of mental health and substance use disorder treatment claims,” signaling a pattern of legal challenges over access to care.

If the Ninth Circuit rules against UnitedHealth’s preemption defense, it could unleash a wave of state-level litigation against other major Medicare Advantage providers. State attorneys general and consumer protection agencies would be newly empowered to investigate and prosecute deceptive practices. Such a precedent would force a reckoning within the industry, potentially compelling insurers to overhaul their marketing strategies and care management protocols to comply with a patchwork of robust state laws, fundamentally altering the balance between corporate profit and patient welfare.